Claudia Fumarola

3.4k citations

61 papers · 2.8k indexed · 1 hit paper · h-index 33

Molecular Biology top 5%
Oncology top 2%
Pulmonary and Respiratory Medicine top 2%
Cancer Research top 5%
Epidemiology top 10%

Co-authors: Roberta Alfieri Mara Bonelli Pier Giorgio Petronini Silvia La Monica Andrea Cavazzoni Guido Guidotti Maricla Galetti Daniele Cretella
Topics: Lung Cancer Treatments and Mutations (22 papers)PI3K/AKT/mTOR signaling in cancer (15 papers)HER2/EGFR in Cancer Research (9 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: The EMBO Journal PLoS ONE The Journal of Physiology
Partner nations: Italy United Kingdom United States

In The Last Decade

Claudia Fumarola

60 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

2014 390 citations Claudia Fumarola, Mara Bonelli et al. Biochemical Pharmacology profile →

Peers

Countries citing papers authored by Claudia Fumarola

Since Specialization

Citations

This map shows the geographic impact of Claudia Fumarola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Fumarola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Fumarola more than expected).

Fields of papers citing papers by Claudia Fumarola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Fumarola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Fumarola. The network helps show where Claudia Fumarola may publish in the future.

Co-authorship network of co-authors of Claudia Fumarola

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Fumarola. A scholar is included among the top collaborators of Claudia Fumarola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Fumarola. Claudia Fumarola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 2024 ·Biochemical Pharmacology ·(unknown),Roberta Alfieri,Claudia Fumarola,Mara Bonelli,Maricla Galetti,Andrea Cavazzoni,Graziana Digiacomo,(unknown),Federica Vacondio,Alessio Lodola,Marco Mor,Roberta Minari,Marcello Tiseo,Silvia La Monica,Pier Giorgio Petronini	4
2	Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 2023 ·Targeted Oncology ·Francesco Volta,Silvia La Monica,Alessandro Leonetti,Letizia Gnetti,Mara Bonelli,Andrea Cavazzoni,Claudia Fumarola,Maricla Galetti,(unknown),Roberta Minari,Pier Giorgio Petronini,Marcello Tiseo,Roberta Alfieri	8
3	Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 2022 ·Cells ·(unknown),Silvia La Monica,Marcello Tiseo,Roberta Alfieri,Claudia Fumarola	48
4	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer 2020 ·Cancers ·Andrea Cavazzoni,Graziana Digiacomo,Roberta Alfieri,Silvia La Monica,Claudia Fumarola,Maricla Galetti,Mara Bonelli,Daniele Cretella,Valeria Barili,Alessandra Zecca,Elisa Giovannetti,Michelangelo Fiorentino,Marcello Tiseo,Pier Giorgio Petronini,Andrea Ardizzoni	36
5	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 2020 ·Frontiers in Oncology ·Graziana Digiacomo,Claudia Fumarola,Silvia La Monica,Mara Bonelli,Daniele Cretella,Roberta Alfieri,Andrea Cavazzoni,Maricla Galetti,Patrizia Bertolini,Gabriele Missale,Pier Giorgio Petronini	25
6	Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 2019 ·Targeted Oncology ·Silvia La Monica,Roberta Minari,Daniele Cretella,Mara Bonelli,Claudia Fumarola,Andrea Cavazzoni,Maricla Galetti,Graziana Digiacomo,Federica Riccardi,Pier Giorgio Petronini,Marcello Tiseo,Roberta Alfieri	38
7	Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 2018 ·Biochemical Pharmacology ·Claudia Fumarola,Pier Giorgio Petronini,Roberta Alfieri	28
8	Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 2018 ·European Journal of Medicinal Chemistry ·Riccardo Castelli,(unknown),Andrea Cavazzoni,Mara Bonelli,Federica Vacondio,Francesca Ferlenghi,Donatella Callegari,Cláudia Silva,Silvia Rivara,Alessio Lodola,Graziana Digiacomo,Claudia Fumarola,Roberta Alfieri,Pier Giorgio Petronini,Marco Mor	11
9	Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 2017 ·European Journal of Medicinal Chemistry ·Dominga Rogolino,Andrea Cavazzoni,Anna Gatti,Matteo Tegoni,Giorgio Pelosi,Vincenzo Verdolino,Claudia Fumarola,Daniele Cretella,Pier Giorgio Petronini,Mauro Carcelli	61
10	Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells 2017 ·Neoplasia ·Mara Bonelli,Graziana Digiacomo,Claudia Fumarola,Roberta Alfieri,Federico Quaini,Angela Falco,Denise Madeddu,Silvia La Monica,Daniele Cretella,Andrea Ravelli,Paola Ulivi,Michela Tebaldi,Daniele Calistri,Angelo Delmonte,Luca Ampollini,Paolo Carbognani,Marcello Tiseo,Andrea Cavazzoni,Pier Giorgio Petronini	82
11	Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations 2015 ·Molecular Cancer Therapeutics ·Mara Bonelli,Andrea Cavazzoni,Francesca Saccani,Roberta Alfieri,Federico Quaini,Silvia La Monica,Maricla Galetti,Daniele Cretella,Cristina Caffarra,Denise Madeddu,Caterina Frati,Costanza Annamaria Lagrasta,Angela Falco,(unknown),Claudia Fumarola,Marcello Tiseo,Pier Giorgio Petronini,Andrea Ardizzoni	32
12	Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 2015 ·PLoS ONE ·Maricla Galetti,Pier Giorgio Petronini,Claudia Fumarola,Daniele Cretella,Silvia La Monica,Mara Bonelli,Andrea Cavazzoni,Francesca Saccani,Cristina Caffarra,Roberta Andreoli,Antonio Mutti,Marcello Tiseo,Andrea Ardizzoni,Roberta Alfieri	54
13	Targeting PI3K/AKT/mTOR pathway in non small cell lung cancerbreakdown → 2014 ·Biochemical Pharmacology ·Claudia Fumarola,Mara Bonelli,Pier Giorgio Petronini,Roberta Alfieri	390
14	Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 2011 ·Molecular Cancer ·Roberta Alfieri,Maricla Galetti,(unknown),Roberta Andreoli,Paola Mozzoni,Andrea Cavazzoni,Mara Bonelli,Claudia Fumarola,Silvia La Monica,Elena Galvani,Giuseppe De Palma,Antonio Mutti,Marco Mor,Marcello Tiseo,E. Mari,Andrea Ardizzoni,Pier Giorgio Petronini	37
15	Synergistic activity of letrozole and sorafenib on breast cancer cells 2010 ·Breast Cancer Research and Treatment ·Mara Bonelli,Claudia Fumarola,Roberta Alfieri,Silvia La Monica,Andrea Cavazzoni,Maricla Galetti,Rita Gatti,Silvana Belletti,Adrian L. Harris,Stephen B. Fox,Dean B. Evans,Mitch Dowsett,Lesley‐Ann Martin,Alberto Bottini,Daniele Generali,Pier Giorgio Petronini	32
16	Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 2010 ·Biochemical Pharmacology ·Maricla Galetti,Roberta Alfieri,Andrea Cavazzoni,Silvia La Monica,Mara Bonelli,Claudia Fumarola,Paola Mozzoni,Giuseppe De Palma,Roberta Andreoli,Antonio Mutti,Marco Mor,Marcello Tiseo,Andrea Ardizzoni,Pier Giorgio Petronini	29
17	Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 2008 ·Cancer Research ·Mara Bonelli,Claudia Fumarola,Roberta Alfieri,Rita Gatti,Silvana Belletti,Silvia La Monica,Maricla Galetti,Andrea Cavazzoni,(unknown),Alberto Bottini,(unknown),Mark Lynch,Adrian L. Harris,Stephen B. Fox,Daniele Generali	1
18	Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 2006 ·The Journal of Physiology ·Roberta Alfieri,Mara Bonelli,Andrea Cavazzoni,Maurizio Brigotti,Claudia Fumarola,Piero Sestili,Paola Mozzoni,Giuseppe De Palma,Antonio Mutti,Domenica Carnicelli,Federica Vacondio,Claudia Silva,Angelo F. Borghetti,Kenneth P. Wheeler,Pier Giorgio Petronini	57
19	Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 2006 ·Cancer Letters ·Andrea Cavazzoni,Maricla Galetti,Claudia Fumarola,Roberta Alfieri,Luca Roz,Francesca Andriani,Paolo Carbognani,Michele Rusca,Gabriella Sozzi,P. G. Petronini	15
20	Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 2004 ·Journal of Cellular Physiology ·Claudia Fumarola,Silvia La Monica,Guido Guidotti	56

About Claudia Fumarola

Claudia Fumarola is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 61 papers that have together received 2.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and HER2/EGFR in Cancer Research (9 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (536 citations) and Pulmonary and Respiratory Medicine (985 citations). Claudia Fumarola has collaborated with scholars based in Italy, United Kingdom and United States. Frequent co-authors include Roberta Alfieri, Mara Bonelli, Pier Giorgio Petronini, Silvia La Monica, Andrea Cavazzoni, Guido Guidotti, Maricla Galetti, Daniele Cretella, Marcello Tiseo and Abelardo López‐Rivas. Their work appears in journals such as The EMBO Journal, PLoS ONE and The Journal of Physiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact